Milestone Pharmaceuticals Inc. Q3 2026 Earnings Call Summary Moby Intelligence Fri, November 13, 2026 at 5:02 PM EST 3 min read NVDA -2.64% MIST -18.27% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Transitioned from a contracted sales model to an internal team of 45 dedicated representatives to reduce overhead and gain direct control over high-value territory targeting.
Achieved a 50% quarter-over-quarter increase in CARDAMYST prescriptions by focusing on electrophysiologists and high-prescribing cardiology accounts.
Expanded commercial insurance coverage to approximately two-thirds of lives, up from 50% in the prior quarter, which management believes will improve revenue realization over time.
Implemented a 30% reduction in operating expenses through organizational streamlining, including the departure of the CFO and CMO and the elimination of low-impact marketing programs.
Refocused the field strategy on approximately 5,000 high-value healthcare providers who manage a disproportionate number of PSVT patients to drive depth of prescribing.
Internalized data systems and analytical capabilities to better identify effective promotional activities and optimize resource allocation during the growth phase.
Attributed steady script growth to increased provider awareness and positive patient feedback, which management views as a natural amplifier for expanded usage.
Extended the operating cash runway into late 2028, covering the anticipated Phase III readout for the ReVeRA-301 study in AFib-RVR.
Anticipates a Phase III data readout for the ReVeRA-301 trial in the second half of 2028, targeting a market management believes is substantially larger than PSVT.
Expects prescription growth to continue inflecting in Q4 2026, though management cautioned that Q1 2027 may see seasonal flattening due to insurance plan resets.
Plans to grow Medicare revenue primarily through medical necessity exception pathways rather than pursuing broad Part D coverage that would require high rebates.
Forecasts that the transition to an in-house sales force and streamlined operations will be fully completed by the first quarter of 2027.
Incurred approximately $2 million in one-time charges related to severance and conversion fees for the workforce reduction and sales force internalization.
Amended the note purchase agreement with RTW Investments LP to extend the payment-in-kind interest period from March 2027 to March 2029.
Reported that the 45-person sales team was optimized from 60 individuals in August by selecting the best-performing territories and representatives.
Management expects Q4 growth to inflect as the optimized 45-rep team focuses on depth within high-value accounts rather than just broad reach.
While electrophysiologists are the primary early adopters, clinical cardiologists are expected to deliver more long-term volume as they manage patients without ablation options.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
The study is event-driven, targeting 150 events from an enrollment of 500-700 patients over a projected two-year timeline.
The trial is powered to show symptomatic benefit on a seven-point Likert scale, aiming for a significant delta between etripamil and placebo.
Management acknowledged high interest from emergency services but is prioritizing the outpatient market due to the heavy operational lift required for hospital protocols.
The interim strategy focuses on establishing discharge protocols so patients leave the ER with a prescription to avoid future emergency visits.
The primary friction point is the lack of new drug options in the category for 30 years, requiring a period of adjustment for physicians to adopt new treatment habits.
Restructuring measures are intended to provide the necessary time for this market shift while maintaining a sustainable cost structure.
Retail distribution is working effectively, with fill rates benchmarking well against similar episodic products.
The company is deploying field-based reimbursement specialists to assist offices with prior authorizations to reduce prescription abandonment.
